The potential of targeted therapy with radiolabeled peptides has been reported in several clinical trials. Although there have been many improvements in dose estimation, a general and reliable dosimetric approach in peptide receptor radionuclide therapy (PRRT) is still a matter of debate. This article reviews the methods for PRRT dosimetry and the results presented in the literature. Radiopharm...

Purpose: A standard imaging protocol for monitoring and predicting the response to Peptide Receptor Radionuclide Therapy (PRRT) has not been established yet. The aim of this study was to evaluate the response to PRRT by quantitative SPECT-CT and assess the value of SPECT-CT over routine planar scintigraphy in predicting the outcome

A practical guidance document on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumors is being published this month in the European Journal of Nuclear Medicine and Molecular Imaging (1). This document is the result of close collaboration among experts in the field of PRRNT from the International Atomic Energy Agency; the Radionuclide Therapy, Oncology, Dosimetry, and Radiophar...

Somatostatin receptor positron emission tomography/computed tomography using 68Ga-labeled somatostatin analogs is the mainstay for the evaluation of receptor status in neuroendocrine tumors (NETs). This translates towards better therapy options, with increasing evidence of peptide receptor radionuclide therapy (PRRT) as the treatment of choice for advanced or progressive NETs. There are benefit...

Historically, molecular imaging of somatostatin receptor (SSTR) expression in patients with neuroendocrine tumors (NET) was performed using SSTR scintigraphy (SRS). Sustained advances medical have led to its gradual replacement positron-emission tomography (SSTR-PET). The higher sensitivity comparison SRS on the one hand and conventional cross-sectional imaging, other hand, enables more accurat...